The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 19, 2024
Filed:
Jan. 22, 2016
Applicant:
Helix Biopharma Corporation, Toronto, CA;
Inventors:
Heman Chao, Aurora, CA;
Wah Yau Wong, Edmonton, CA;
Baomin Tian, Edmonton, CA;
Kimberly Jayne Gaspar, Saskatoon, CA;
Praveen Kumar, Saskatoon, CA;
Assignee:
HELIX BIOPHARMA CORPORATION, Toronto, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 9/80 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6815 (2017.08); A61K 39/39558 (2013.01); A61K 47/6853 (2017.08); A61K 47/6857 (2017.08); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/3023 (2013.01); C12N 9/80 (2013.01); C07K 2317/22 (2013.01); C07K 2317/569 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01);
Abstract
Pharmaceutical compositions comprising antibody-urease conjugates and substantially free of unconjugated urease are disclosed. These compositions are prepared by a method that does not require chromatographic purification. These pharmaceutical compositions have utility in the treatment of cancer by antibody-directed enzyme prodrug therapy wherein the urease converts endogenous urea into ammonia in situ to induce cytotoxicity.